Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: interim results of a patient survey of ravulizumab (ALXN1210) and eculizumab. Abstract presented at Academy of Managed Care & Specialty Pharmacy Annual Meeting; San Diego, CA
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.